Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLENVU vs COLPREP KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
Col Prep Kit contains polyethylene glycol (PEG) 3350 and electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate). PEG is an osmotic agent that causes water retention in the colon, increasing stool volume and stimulating bowel movements. Electrolytes maintain fluid and electrolyte balance, preventing shifts during bowel cleansing.
FDA-approved: Bowel cleansing prior to colonoscopy in adults.,Off-label: Bowel preparation for colorectal surgery or other procedures requiring colonic cleansing.
Bowel cleansing prior to colonoscopy
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500m L, administered orally as a split-dose regimen: first dose (2 sachets in 500m L water) at 6-9 pm on the day before colonoscopy, followed by additional 500m L of clear fluids; second dose (2 sachets in 500m L water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500m L of clear fluids.
Colprep Kit (sodium picosulfate/magnesium oxide/citric acid) for bowel cleansing: Two doses administered orally. First dose: 1 sachet reconstituted in water in the evening prior to colonoscopy. Second dose: 1 sachet on the morning of the procedure, at least 5 hours before the procedure. Each sachet is dissolved in 150 m L water, diluted to a total volume of 500 m L, and consumed over 30-60 minutes followed by additional water.
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
Not applicable; colonic lavage solution with negligible systemic absorption.
Polyethylene glycol 3350 is minimally absorbed and eliminated unchanged in feces. Ascorbic acid and sodium ascorbate are absorbed and metabolized via normal pathways (e.g., oxidation, conjugation). Sodium sulfate is absorbed and excreted primarily in urine.
Polyethylene glycol (PEG) 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and excreted renally.
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Primarily fecal as unabsorbed drug; minimal renal excretion (<1%).
<5% bound to plasma proteins (due to minimal absorption).
Not applicable; not absorbed systemically.
Not applicable (confined to GI tract; systemic Vd not measurable).
Not applicable; confined to gastrointestinal lumen.
Oral: <0.1% systemically available due to lack of absorption.
Oral: <0.1% (negligible systemic absorption).
Contraindicated in patients with estimated glomerular filtration rate (e GFR) < 30 m L/min/1.73 m² due to risk of acute phosphate nephropathy. No dose adjustment recommended for e GFR ≥ 30 m L/min/1.73 m².
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-to-moderate impairment; use with caution and ensure adequate hydration.
No specific dosage adjustment based on Child-Pugh classification is provided by the manufacturer. Use with caution in patients with severe hepatic impairment due to potential electrolyte disturbances.
No dose adjustment required for mild-to-moderate hepatic impairment. Safety not established in severe hepatic impairment (Child-Pugh C); use with caution.
Not approved for use in pediatric patients (age < 18 years). Safety and efficacy not established.
Safety and efficacy not established in pediatric patients (<18 years). No approved pediatric dosing.
No specific dose adjustment required for elderly patients, but caution is advised due to increased risk of dehydration, electrolyte abnormalities, and renal impairment. Ensure adequate hydration and monitor renal function.
No specific dose adjustment. Use with caution due to increased risk of electrolyte disturbances and dehydration; ensure adequate hydration and monitor renal function.
No FDA black box warning.
No FDA black box warning.
Serious fluid and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, seizures).,Cardiac arrhythmias in patients with electrolyte imbalances or prolonged QT interval.,Renal impairment: Risk of acute tubular necrosis and nephrocalcinosis.,Mucosal ulceration or colitis (rare).,Sulfate absorption may cause metabolic acidosis in susceptible patients.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypomagnesemia, seizures).,Cardiac arrhythmias in patients with electrolyte imbalances or prolonged QT interval.,Renal impairment: risk of acute phosphate nephropathy if using sodium phosphate-based products; however, this product contains sulfate and magnesium.,Gastric retention or gastrointestinal obstruction: do not use in patients with ileus, gastric retention, bowel obstruction, or perforation.,Aspiration risk: use with caution in patients with impaired gag reflex or those prone to regurgitation.
Gastrointestinal obstruction or ileus.,Perforation of the gastrointestinal tract.,Gastric retention or gastroparesis.,Toxic colitis or toxic megacolon.,Known hypersensitivity to any component of PLENVU.
Gastrointestinal obstruction or ileus,Bowel perforation,Toxic colitis or toxic megacolon,Gastric retention,Known hypersensitivity to any component of the kit
Avoid solid foods, dairy products, and any colored liquids (especially red, purple, or orange) during preparation. Patients must consume only clear liquids (e.g., water, clear broth, apple juice, clear gelatin, black coffee or tea without milk) to maintain hydration. Alcohol should be avoided due to dehydrating effects and potential interaction with preparation.
Avoid all solid foods, milk, yogurt, and any beverages containing pulp or red/purple coloring. Only clear liquids are permitted: water, clear broth (fat-free), apple juice, white grape juice, clear sodas (e.g., ginger ale), black coffee or tea (no milk or creamer). No alcohol. Ensure no dairy or citrus juices.
PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, and macrogol) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, no evidence of teratogenicity was observed at doses up to 2 times the maximum recommended human dose. However, the osmotic laxative effect may cause fluid and electrolyte shifts, potentially affecting fetal perfusion. Use during pregnancy should be reserved for cases where bowel cleansing is essential and benefits outweigh risks, particularly in the first trimester due to theoretical concerns of dehydration or electrolyte imbalance.
Colprep Kit contains polyethylene glycol and electrolytes. Polyethylene glycol is not teratogenic in animal studies; no human studies available. Risk to fetus during all trimesters is considered low due to minimal systemic absorption.
It is unknown whether PLENVU or its components are excreted in human breast milk. Polyethylene glycol is poorly absorbed systemically after oral administration, suggesting minimal transfer into breast milk. However, because many drugs are excreted in human milk, caution should be exercised when PLENVU is administered to a nursing woman. The M/P ratio has not been established for this combination product. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for PLENVU.
Polyethylene glycol is not absorbed systemically and is unlikely to pass into breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No specific dosing adjustments are recommended for PLENVU in pregnancy; however, clinical trials excluded pregnant women. The standard dose (two sachets: split-dose regimen) should be used cautiously with close monitoring for dehydration and electrolyte imbalances. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered GI motility) may affect drug dispersal, but no formal studies exist. Consider reducing fluid volume if contraindicated, but no dose reduction has been established.
No dose adjustment required in pregnancy due to minimal systemic absorption. Use caution if maternal comorbidities such as renal impairment or congestive heart failure present.
PLENVU is a polyethylene glycol (PEG)-based bowel preparation used for colonoscopy. Adequate hydration is critical to prevent electrolyte abnormalities; ensure patients drink additional clear fluids as directed. Split-dose regimen (half dose evening before, remainder morning of procedure) improves tolerance and colon cleansing. Caution in patients with renal impairment, CHF, or electrolyte disturbances; monitor for volume depletion. Not recommended in patients with GI obstruction, ileus, or toxic colitis. May reduce absorption of oral medications (e.g., contraceptives, antidiabetics, anticoagulants); advise temporal separation.
Col Prep Kit contains sodium phosphate monobasic and sodium phosphate dibasic. Use with caution in patients with renal impairment, heart failure, or electrolyte abnormalities due to risk of phosphate nephropathy. Ensure adequate hydration before, during, and after administration. Monitor serum electrolytes, BUN, and creatinine in at-risk patients.
Take PLENVU exactly as prescribed; follow the split-dose regimen for best results.,Drink the full amount of clear liquids recommended (including water) to prevent dehydration.,Avoid solid foods, dairy, red/purple liquids, and alcohol during preparation.,Expect frequent, watery bowel movements; stay near a bathroom.,If you miss a dose, consult your healthcare provider; do not double the dose.,Inform your doctor about all medications you take, especially diabetes meds, blood thinners, and diuretics.,Stop taking oral medications (e.g., contraceptives, hypoglycemics) as directed during prep; discuss alternative contraception.,Seek medical help if you experience severe vomiting, dizziness, fainting, or signs of allergic reaction.
Take the medication exactly as prescribed, usually as a split dose the day before and the day of the procedure.,Drink plenty of clear liquids (e.g., water, clear broth, apple juice) to prevent dehydration.,Do not eat any solid food while taking this medication; only consume clear liquids.,Expect frequent, watery bowel movements starting within 1-2 hours of the first dose.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration (e.g., dizziness, decreased urination).,Stop taking other laxatives or stool softeners unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLENVU vs COLPREP KIT, answered by our medical review team.
PLENVU is a Osmotic Laxative that works by PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.. COLPREP KIT is a Osmotic Laxative that works by Col Prep Kit contains polyethylene glycol (PEG) 3350 and electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate). PEG is an osmotic agent that causes water retention in the colon, increasing stool volume and stimulating bowel movements. Electrolytes maintain fluid and electrolyte balance, preventing shifts during bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLENVU and COLPREP KIT depend on the specific clinical indication. These are both Osmotic Laxative agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLENVU is: 2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500m L, administered orally as a split-dose regimen: first dose (2 sachets in 500m L water) at 6-9 pm on the day before colonoscopy, followed by additional 500m L of clear fluids; second dose (2 sachets in 500m L water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500m L of clear fluids.. The standard adult dose of COLPREP KIT is: Colprep Kit (sodium picosulfate/magnesium oxide/citric acid) for bowel cleansing: Two doses administered orally. First dose: 1 sachet reconstituted in water in the evening prior to colonoscopy. Second dose: 1 sachet on the morning of the procedure, at least 5 hours before the procedure. Each sachet is dissolved in 150 m L water, diluted to a total volume of 500 m L, and consumed over 30-60 minutes followed by additional water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLENVU and COLPREP KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLENVU is classified as Category C. PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, and macrogol) is classified as FDA Pregnancy Category C. There are no adequate and well-controlle. COLPREP KIT is classified as Category C. Colprep Kit contains polyethylene glycol and electrolytes. Polyethylene glycol is not teratogenic in animal studies; no human studies available. Risk to fetus during all trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.